J&J and Allergan are racing to shake up the $9 billion market for depression treatments for the first time in decades (JNJ, SAGE, AGN)

5:00am PST - February 25th, 2019    ketamine - Business Insider

Johnson & Johnson, Allergan, and Sage are racing to launch the first new depression drugs in 35 years. Cheered by a recent regulatory nod for a new drug called esketamine, analysts are hopeful that other biotechs with novel antidepressants in their pipelines …